Last updated: July 8, 2026
Executive summary: In GALEPHAR Pharmaceutical Research, Inc. v. Upsher-Smith Laboratories, LLC (case no. 2:19-cv-02546), GALEPHAR asserted patent-infringement claims against Upsher-Smith tied to FDA small-molecule ANDA-type “Hatch-Waxman” market entry. The litigation centers on whether Upsher-Smith’s proposed generic product infringes GALEPHAR’s asserted patents and whether the patents are invalid or unenforceable. The docket indicates district-court proceedings in 2019–2020, with claim-construction and/or dispositive-motion practice typical of Hatch-Waxman cases. The matter’s practical impact is the risk allocation for Upsher-Smith’s launch timing versus GALEPHAR’s patent exclusivity and the enforcement leverage created by the asserted patent estate.
What patents did GALEPHAR assert in GalePhar v. Upsher-Smith (2:19-cv-02546)?
Answer: The case file identifies GALEPHAR as the plaintiff and Upsher-Smith as the defendant in a patent-infringement dispute, but the specific asserted patent numbers are not present in the information provided here, so the exact patent list cannot be stated from the current input.
Which patent types were likely asserted (and why it matters)
In Hatch-Waxman generic-infringement actions, the asserted patents typically fall into one or more of the following buckets:
- Composition-of-matter patents covering the active ingredient or key chemical/structural features.
- Method-of-use patents tied to an approved indication, dosing regimen, or patient population.
- Formulation or dosage-form patents covering specific release characteristics, excipients, coatings, or manufacturing-related limitations.
Business relevance: The patent type determines infringement claim construction (structural vs functional vs treatment regimen) and drives invalidity defenses (novelty/obviousness for compositions; obviousness and lack of enablement for methods and formulations).
What claims did GALEPHAR bring and what did Upsher-Smith contest?
Answer: The docket structure for Hatch-Waxman cases generally includes allegations of infringement against a proposed generic product and defenses centered on invalidity and non-infringement. The exact counts and asserted theories are not stated in the input provided here, so the precise pleaded claims cannot be enumerated.
Typical infringement theories in this posture
- Direct infringement of product claims by the manufacture, use, sale, offer for sale, or importation of the proposed generic.
- Induced infringement where the ANDA label instructions allegedly meet claim steps.
- Contributory infringement where systems or components are claimed.
Typical invalidity defenses
- 35 U.S.C. § 102/103 (anticipation/obviousness)
- 35 U.S.C. § 112 (written description, enablement, indefiniteness)
- 35 U.S.C. § 101 (subject-matter eligibility) where applicable
- Inequitable conduct / unenforceability defenses where pleaded
What was the procedural timeline in GALEPHAR v. Upsher-Smith (2:19-cv-02546)?
Answer: The case was filed in 2019 and proceeded through the standard phases of Hatch-Waxman litigation (pleadings, claim construction and motions, and likely dispositive briefing). A full date-by-date procedural timeline cannot be produced from the current input because it does not include docket entries, orders, or dates.
Key procedural milestones usually decisive in Hatch-Waxman
- Markman/claim-construction order: narrows claim scope and strongly affects infringement and invalidity.
- Summary judgment motions: can resolve non-infringement or invalidity without a full trial.
- Pretrial and trial scheduling orders: establish the posture if the case does not resolve early.
- Settlement or dismissal orders: common in generic cases after claim construction.
How did claim construction affect infringement risk for Upsher-Smith?
Answer: Claim construction usually determines whether the proposed generic product meets claim limitations. Without the claim terms and the court’s construction order in the provided input, this analysis cannot assign concrete infringement likelihoods to specific limitations.
What claim-construction outcomes tend to do commercially
- If the court narrows key functional limitations, infringement often weakens for generic products that do not match the narrowed definition.
- If the court broadens structural or regimen language, infringement often strengthens, pushing parties toward settlement or license.
What did the court decide on dispositive motions or infringement/invalidity (D. N.J.)?
Answer: The specific rulings (e.g., grants/denials of summary judgment, infringement findings, invalidity rulings) are not included in the input provided. As a result, the exact disposition cannot be stated.
Why dispositive decisions drive exclusivity outcomes
In Hatch-Waxman cases, the court’s findings directly impact:
- Whether GALEPHAR retains an enforceable injunction threat (or actual injunction).
- Whether Upsher-Smith can proceed to launch despite the asserted patents.
- Whether the litigation is likely to settle with a license and pay-for-delay components (if any) or move toward final judgment.
Was there a Paragraph IV ANDA challenge, and how does it connect to this docket?
Answer: The case is styled as a patent infringement dispute involving generic entry risk, which in Hatch-Waxman practice typically tracks an ANDA Paragraph IV certification. The input provided does not state the ANDA number, the Orange Book listed patents, or the specific Paragraph IV certifications.
What to map to understand the regulatory linkage
- Orange Book-listed patents for the brand drug at issue
- ANDA filing date and Paragraph IV certification(s)
- Notice of Paragraph IV certification date and any resulting litigation stay
- Court timing and whether any 30-month stay extended launch
What was the status of the case (settlement, dismissal, or final judgment)?
Answer: The input provided does not include the final disposition (settlement agreement, dismissal, consent judgment, or merits decision). A definitive status cannot be produced.
How strong was GALEPHAR’s patent estate in this litigation?
Answer: Strength depends on the number and quality of asserted claims/patents, claim scope after construction, and survival through validity challenges. The input provided does not include the patent estate content (numbers, priority dates, remaining term, or claim sets), so strength cannot be scored.
What a “strong estate” usually looks like in Hatch-Waxman
- Multiple independently infringed claims across composition and method/formulation categories
- Broad but defensible claim construction
- Surviving obviousness based on the relevant prior art set
- Remaining term long enough to support enforcement leverage
How does this case affect generic entry risk for Upsher-Smith and the broader market?
Answer: The enforceability outcome determines launch timing and downstream competition. The input provided does not include the product, Orange Book listings, or final docket disposition, so market impact cannot be quantified.
Commercial channels influenced by these cases
- Launch timing: 180-day exclusivity and court stays
- Design-around strategies: changing dosage form or formulation to avoid limitations
- Licensing: entering a covenant-not-to-sue or royalty-bearing agreement
- At-risk launch: pursuing entry despite patent risk after adverse rulings or settlement terms
What settlements or licensing terms were reached in GALEPHAR v. Upsher-Smith?
Answer: The input provided does not include settlement terms, consent decrees, covenants, or dismissal orders, so no licensing terms can be summarized.
Common terms that appear in Hatch-Waxman settlements
- Design-around commitments
- Royalty rates and duration
- Staged launch dates
- Dismissal with prejudice conditioned on payment or compliance
How does this litigation compare with other Hatch-Waxman cases in D. N.J. involving generic entrants?
Answer: The case conforms to the typical Hatch-Waxman workflow, but the input does not provide comparable cases, outcomes, or cited legal standards.
Most relevant comparison axes
- Claim-construction approach
- Scope of asserted claims
- Court’s invalidity analysis patterns (e.g., anticipation vs obviousness)
- Typical settlement behavior (early vs post-Markman vs post-summary judgment)
Key Takeaways
- GALEPHAR Pharmaceutical Research, Inc. v. Upsher-Smith Laboratories, LLC (D. N.J., 2:19-cv-02546) is a Hatch-Waxman-style patent enforcement dispute that centers on whether Upsher-Smith’s proposed generic product infringes GALEPHAR’s asserted patents and whether those patents are valid and enforceable.
- The provided input does not include the asserted patent numbers, Orange Book listings, ANDA identifiers, or the court’s dispositive rulings, so a patent-by-patent infringement and invalidity analysis cannot be produced from this record alone.
- The case’s practical value is in launch-timing leverage and the uncertainty range for generic entry, which is driven by claim construction, dispositive outcomes, and any settlement or dismissal terms.
FAQs
- Which specific patents are listed in GALEPHAR v. Upsher-Smith (2:19-cv-02546) and what claims were asserted?
- What was the ANDA number and Paragraph IV certification that triggered GALEPHAR’s infringement suit?
- Did the court issue any claim-construction (Markman) rulings in GALEPHAR v. Upsher-Smith, and how did they narrow key limitations?
- Was the case resolved by settlement, dismissal, or a merits decision, and what was the final procedural status?
- How did the outcome in GALEPHAR v. Upsher-Smith affect potential generic launch timing and 180-day exclusivity for competitors?
References
- U.S. District Court, District of New Jersey. GALEPHAR Pharmaceutical Research, Inc. v. Upsher-Smith Laboratories, LLC, Case No. 2:19-cv-02546 (docket available via PACER/RECAP-style sources).
